Wedbush initiated coverage on Ovid Therapeutics with a new price target
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $8.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | Outperform → Perform | Oppenheimer | |
| 4/30/2024 | $9.00 | Buy | B. Riley Securities |
| 4/29/2024 | $9.00 | Buy | H.C. Wainwright |
| 4/5/2024 | $8.00 | Outperform | Wedbush |
| 12/21/2023 | $11.00 | Buy | BTIG Research |
| 10/13/2023 | $8.00 | Outperform | Oppenheimer |
| 8/25/2021 | $4.50 → $4.00 | Neutral | Citigroup |
DEFA14A - Ovid Therapeutics Inc. (0001636651) (Filer)
DEF 14A - Ovid Therapeutics Inc. (0001636651) (Filer)
10-Q - Ovid Therapeutics Inc. (0001636651) (Filer)